Myoblast transfer therapy: Is there any light at the end of the tunnel?

Acta Myologica

Volumn 24, Issue 2, 2005, Pages 128-133

  Mouly, Vincent ^a   Aamiri, A ^b   Perie S ^a,c   Mamchaoui, K ^a   Barani, A ^a   Bigot, A ^a   Bouazza, B ^a   Francois V ^a   Furling, D ^a   Jacquemin, V ^a   Negroni, E ^a   Riederer, I ^a   Vignaud, A ^a   St Guily, J L ^a,c   Butler Browne, G S ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b FACULTÉ DES SCIENCES   (Morocco)

^c HÔPITAL TENON   (France)

Author keywords

Cellular grafts; Dispersion; Mitotic clock; Muscular dystrophy; Myoblast Transfer Therapy (MTT); Proliferation; Stem cells

Indexed keywords

CD133 ANTIGEN;

ALLOGRAFT; CELL DEATH; CELL TRANSFER; CELL TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; DUCHENNE MUSCULAR DYSTROPHY; FASCIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE THERAPY; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MUSCULAR DYSTROPHY; MYOBLAST; MYOBLAST TRANSFER THERAPY; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ANIMALS; GENE THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; MYOBLASTS, SKELETAL; REGENERATION; TISSUE ENGINEERING;

EID: 33344466851     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Mauro A. Satellite cell of skeletal muscle fibres. J. Biophy. Biochem. Cytol. 1961;9:493-5.
2. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279:1528-30.
3. Torrente Y, Belicchi M, Sampaolesi M, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J. Clin. Invest. 2004;114:182-95.
4. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003;301: 487-92.
5. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci 2000;113:2299-308.
6. Ferrari G, Stornaiuolo A, Mavilio F. Failure to correct murine muscular dystrophy. Nature 2001;411:1014-5.
7. Sherwood RI, Christensen JE, Conboy IM, et al. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004;119:543-54.
8. Gros J, Manceau M, Thome V, Marcelle C. A common somitic origin for embryonic muscle progenitors and satellite cells. Nature 2005;435:954-8.
9. Montarras D, Morgan J, Collins C, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005;309:2064-7
10. Kassar-Duchossoy L, Giacone E, Gayraud-Morel B, et al. Pax3/Pax7 mark a novel population of primitive myogenic cells during development. Genes Dev. 2005;19:1426-31.
11. Partridge T. Reenthronement of the muscle satellite cell. Cell 2004;119:447-8
12. Partridge T. Myoblast transplantation. Neuromuscul Disord. 2002;Suppl 12:83-6
13. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989;337:176-9.
14. Huard J, Bouchard JP, Roy R, et al. Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve 1992;15:550-60.
15. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 1999;144:1113-22.
16. Guerette B, Skuk D, Celestin F et al. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J Immunol. 1997;159:2522-3.
17. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
18. Decary S, Mouly V., Butler-Browne GS. Telomere length as a tool to monitor satellite cell amplification for cell-mediated gene therapy. Hum. Gene Ther. 1996;7:1347-50.
19. Decary S, Mouly V, Ben Hamida C, et al. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell mediated gene therapy. Hum. Gene Ther. 1997;8:1429-38.
20. Renault V, Piron-Hamelin G, Forestier C, et al. Skeletal muscle regeneration and the mitotic clock. Exp. Geront. 2000;35:711-9.
21. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995;92:4818-22.
22. Wright WE, Shay JW. Historical claims and current interpretations of replicative ageing. Nature Biotech 2002;20:682-8.
23. Kipling D. Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur. J. Cancer 1997;33:792-800.
24. Skuk D, Tremblay J. Cell therapies for inherited myopathies. Curr Opin Rheumatol. 2003;15:723-9.
25. Lafreniere JF, Mills P, Tremblay JP, Fahime EE. Growth factors improve the in vivo migration of human skeletal myoblasts by modulating their endogenous proteolytic activity. Transplantation. 2004;77:1741-7.
26. Skuk D, Roy B, Goulet M et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther. 2004;9:475-82.
27. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R, Tremblay JP. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve. 1994;17:1407-15.
28. Wernig A, Irintchev A. "Bystander" damage of host muscle caused by implantation of MHC-compatible myogenic cells. J Neurol Sci. 1995;130:190-6.
29. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003;41:1078-83.
30. Decary S, Ben Hamida C, Mouly V, et al. Shorter telomeres in dystrophic muscle: evidence for extensive regeneration in young infants. Neurom. Dis. 2000;10:113-20.
31. nd edition. Engel AG, Franzini-Armstrong C, eds. (New York: McGraw-Hill Company) pp. 1233-45.
32. Tomé FMS, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculo-pharyngeal muscular dystrophy. Neuromusc. Disord. 1997;7(suppl 1):S63-9.
33. Lacau St Guily J, Moine A, Périé S, et al. Role of pharyngeal propulsion as an indicator for upper esophageal sphincter myotomy. Laryngoscope 1995;105:723-7.
34. Périé S, Eymard B, Laccourreye L, et al. Dysphagia in oculo-pharyngeal muscular dystrophy (OPMD): a serie of 22 cases. Neuromusc. Disord. 1997;7 (suppl 1):S96-9.
35. Vilquin JT, Marolleau JP, Sacconi S, et al. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Gene Ther. 2005;12:1651-6.
36. Cooper RN, Irintchev A, Di Santo JP, et al. A new immunodeficient model for human myoblast transplantation. Hum. Gene Ther. 2001;12:823-31.
37. Cooper RN, Thiesson D, Furling D, et al. Extended amplification in vitro and replicative senescence: key factors implicated in the success of human myoblast transplantation. Hum. Gene Ther. 2003;14:1169-79.
38. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 2001;98:42-7.
39. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004;306:1796-9.
40. Collins CA, Olsen I, Zammit PS, et al. Stem cell function, self-renewall, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005; 122:289-301.